Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention

NCT07318103 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2026-04-09

No results posted yet for this study

Summary

Phase II clinical study of HRS-9057 injection in patients with heart failure-induced fluid retention

Conditions

  • Fluid Retention Caused by Heart Failure

Interventions

DRUG

HRS-9057 injection set

HRS-9057 injection set

DRUG

5% Glucose Injection or 0.9% sodium chloride injection

5% Glucose Injection or 0.9% sodium chloride injection

Sponsors & Collaborators

  • Fujian Shengdi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2026-07-31
Completion
2026-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07318103 on ClinicalTrials.gov